Time course of the placebo response and associated factors in clinical trials of biologic agents for ankylosing spondylitis
Year: 2026
Type: article
Study designs: Systematic Review, Meta-Analysis
Abstract: Aims To characterize the time course and influencing factors of placebo response in randomized trials of biologic and targeted synthetic disease-modifying antirheumatic drugs (tsDMARDs) for ankylosing spondylitis (AS).Patients and Methods We systematically searched major electronic databases (up to June 14, 2024) for randomized double-blind placebo-controlled trials of biologics or Janus kinase inhibitors in AS. Model-based meta-analysis with nonlinear mixed-effects modeling was conducted to pool placebo-arm ASAS20 (≥20% improvement by Assessment of SpondyloArthritis International Society criteria) and ASAS40 (≥40% improvement) response trajectories, using an exponential rise-to-maximum model with covariate screening and model validation.Results Thirty-eight trial arms from 36 trials (3046 placebo-treated participants) were included. The estimated maximum response (Pmax) was 31.1% for ASAS20 (90% of Pmax reached at 6.5 weeks) and 18.6% for ASAS40 (90% of Pmax reached at 17.0 weeks). ASAS20 Pmax increased by 2.7% per publication year. Smaller trials, no background therapy, lower male proportion, and lower baseline HLA-B27 positivity were associated with higher placebo response.Conclusions The AS placebo response, particularly for ASAS20, shows a significant upward secular trend. This model provides a quantitative benchmark for trial design, anomalous placebo responses identification, and interpreting efficacy in trials lacking a concurrent placebo arm.
Source: Future Science OA
Language: English
Subfield: Rheumatology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $1,165
OpenAlex ID: W7225772606
